Chai Discovery, a biotech startup with strong backing from OpenAI, recently made headlines with the announcement of a $130 million Series B round. This latest funding round has valued the company at an impressive $1.3 billion, showcasing the high level of confidence and interest in the company’s potential.
Leading the Series B round are prominent investors General Catalyst and Oak HC/FT, with additional participation from Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite Venture Fund, Lachy Groom, SV Angel, as well as new investors Glade Brook and Emerson Collective. With this new injection of capital, Chai Discovery’s total funding now exceeds $225 million, providing a strong foundation for the company’s continued growth and development.
Chai Discovery operates within a rapidly expanding industry that recognizes the power of AI in accelerating the process of drug discovery. The company’s focus on leveraging AI technology to predict interactions between biochemical molecules and develop innovative cures has captured the attention of investors and industry experts alike.
In a previous funding round led by Menlo Ventures, Chai Discovery was praised for its groundbreaking work in building foundation models tailored for drug discovery. The company’s latest AI model, Chai 2, has demonstrated significant advancements in the success rates of de novo antibody design, enabling the creation of custom antibodies from scratch with unparalleled precision.
Josh Meier, Co-Founder and CEO of Chai Discovery, expressed confidence in the company’s latest achievements, stating, “Our latest models can design molecules with properties that mimic actual drugs and address challenging targets that were previously unattainable.” With a background in machine learning and experience at Facebook and OpenAI, Meier brings a wealth of expertise to Chai Discovery’s innovative approach to molecular design.
Founded in 2024, Chai Discovery has quickly established itself as a leader in the biotech industry, with a clear vision to develop a comprehensive “computer-aided design suite” for molecules. The company’s commitment to pushing the boundaries of drug discovery through AI technology sets them apart in a competitive and rapidly evolving landscape.
To stay updated on the latest developments from Chai Discovery and other leading companies in the tech and biotech sectors, be sure to mark your calendars for the upcoming Techcrunch event in San Francisco on October 13-15, 2026. This event promises to showcase groundbreaking technologies and innovations that are shaping the future of industries worldwide.
